Floatz Rating
D29/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
14Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06082843CT.gov A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly | — | Terminated | — | — | — |
NCT05282121CT.gov A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) | — | Terminated | — | — | — |
NCT05161481CT.gov A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Portal Hypertension
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avenciguat (this asset) | Boehringer Ingelheim | P2 | D · 29 |
| Carvedilol | West China Hospital | P4 | BBB |
| Simvastatin | Kafrelsheikh University | P4 | BBB |
| Apsolol | West China Hospital | P4 | BBB |
| Apixaban | Asian Institute Of Medical Sciences | P4 | BB |
| Warfarin | Northern Jiangsu People's Hospital | P4 | BB |
| Dipyridamole | Northern Jiangsu People's Hospital | P4 | BB |
| Aspirin | Northern Jiangsu People's Hospital | P4 | BB |
| Lactulose | University of Michigan | P4 | BB |
+42 more in the Portal Hypertension cohort
Other indications for Avenciguat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Liver Disorder | — | P2 | D · 29 |
| Cirrhosis Of Liver | — | P2 | D · 29 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avenciguat in Portal Hypertension. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avenciguat-portal-hypertension
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →